Oncolytics and Coherus sign supply deal to test pelareorep with LOQTORZI in anal cancer
Oncolytics Biotech and Coherus Oncology have entered a clinical supply agreement to evaluate the oncolytic virus pelareorep together with Coherus’ PD‑1 inhibitor LOQTORZI (toripalimab‑tpzi) in patients with squamous cell anal carcinoma. The study will start in early 2027 at a U.S. cancer centre and will enroll patients whose disease has progressed after standard chemotherapy and checkpoint‑inhibitor therapy. Jared Kelly, CEO of Oncolytics, said the partnership enables a focused assessment of the combination in a hard‑to‑treat population.
Why it matters
The agreement secures a source of LOQTORZI for the trial, allowing Oncolytics to advance its pelareorep program into a second‑line indication. Successful results could broaden the use of the combination across other HPV‑associated cancers, potentially increasing future revenue streams for both companies.
Key facts
- 1Oncolytics Biotech and Coherus Oncology signed a clinical supply agreement to test pelareorep with LOQTORZI in squamous cell anal carcinoma. investing.com
- 2The trial is planned to commence in the first quarter of 2027 at a U.S. cancer centre. investing.com
- 3The study will enroll patients who have progressed after first‑line chemotherapy and checkpoint‑inhibitor treatment. investing.com
- 4Jared Kelly is the Chief Executive Officer of Oncolytics Biotech. investing.com
- 5Pelareorep has been administered to more than 1,200 patients to date. investing.com
- 6On the day of the announcement, Oncolytics shares closed at $0.41, up 7.81%. rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.